Drugs / Halneuron
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06848348 | Feb 2025 → Jul 2026 overdue | chemotherapy-induced neuropathy, chemotherapy-induced toxicity | Dogwood Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Halneuron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06848348 ↗ |
| Route | Subcutaneous | “series of subcutaneous (SC) injections of HAL” NCT06848348 ↗ |